查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1980186

中枢神经系统疗法市场规模、份额、成长及全球产业分析：按类型、应用和地区分類的洞察，2026-2034 年预测

Central Nervous System Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 160 Pages | 商品交期: 请询问到货日

价格

中枢神经系统（CNS）治疗市场成长要素

2025年全球中枢神经系统（CNS）治疗市场规模为1,266.8亿美元，预计2026年将成长至1,386.6亿美元，到2034年将达2,369.4亿美元，2026年至2034年的复合年增长率（CAGR）为6.93%。 2025年，北美市场占据主导地位，占全球市场份额的45.70%。这得益于北美健全的法规结构、较高的治疗可及性以及主要企业的存在。

中枢神经系统（CNS）治疗市场涵盖神经退化性疾病、神经血管疾病、精神疾病和感染性神经系统疾病的治疗方法。阿兹海默症、帕金森氏症、癫痫和多发性硬化症等神经系统疾病的日益普遍，显着地推动了市场扩张。

新冠疫情的影响

新冠疫情对中枢神经系统（CNS）治疗市场造成了负面影响，导致2024年市场规模下降4.2%。製药公司将研发重点转向新冠疫苗和治疗药物，预计2024年销售额将减少1,158.4亿美元。然而，随着需求恢復到疫情前水准以及药物研发活动的重启，市场在2025年得以復苏。

市场驱动因素

神经系统疾病盛行率增加

全球神经系统疾病负担日益加重是成长要素。在美国，约有600万人患有阿兹海默症，预计未来几十年这一数字将显着增加。每年的治疗和护理费用超过3050亿美元，因此对有效的中枢神经系统疗法有着强烈的需求。

此外，多发性硬化症、帕金森氏症、癫痫和精神疾病的病例数量不断增加，患者群体日益扩大。全球人口老化进一步加速了对先进治疗方法的需求。

有前景的在研药物

多款处于后期临床试验阶段的创新分子和生物製药可望提振市场前景。製药公司之间的策略联盟和授权协议正在提高药物研发效率，并扩大全球商业化机会。

市场限制因素

儘管中枢神经系统（CNS）治疗市场具有成长前景，但也面临许多挑战：

  • 严格的监管核准
  • 高昂的研发成本
  • 临床开发週期越来越长。
  • 穿过血脑障壁的难度
  • 关于药物不良反应和安全性的警告

例如，2025年，美国食品药物管理局（FDA）发布了一项关于某些多发性硬化症药物的安全警告，指出其使用可能存在风险。这些因素可能会在预测期内限制市场成长。

市场区隔分析

依疾病类型

  • 到 2026 年，神经退化性疾病将引领市场，占据 47.08% 的市场份额，这主要得益于多发性硬化症和阿兹海默症治疗药物的销售成长。
  • 由于全球意识的提高以及后疫情时代人们所经历的心理压力，对心理健康服务的需求正在增加。
  • 神经血管疾病和感染疾病也是推动市场稳定成长的因素。

药物类别

  • 到 2026 年，免疫调节药物将以 52.08% 的市占率引领市场，这得益于多发性硬化症治疗领域的创新。
  • 干扰素、抗忧郁症、多巴胺促效剂、镇痛药和其他中枢神经系统 (CNS) 药物对总销售额贡献巨大。

依药物类型

  • 到 2026 年，非生物製药将占据市场主导地位，市场份额达 69.05%，这得益于其易于获得监管部门核准和较高的处方率。
  • 在政府支持措施和生物製药产品线不断扩大的推动下，生物製药产业有望稳步成长。

透过分销管道

  • 由于处方药销量高以及人们更倾向于住院治疗，医院药房占据了最大的市场份额。
  • 零售药局和网路药局正在扩张，尤其是在新兴市场。

区域趋势

北美洲

预计到2025年，北美市场规模将达到579.6亿美元，到2026年将达到631.3亿美元。光是美国市场预计到2026年就将达到582.5亿美元。这一增长得益于强大的研发基础设施、高疾病盛行率、FDA的监管支持以及健全的报销体系。

欧洲

欧洲占据第二大市场份额，这得益于其优惠的报销政策和公共医疗保健体系，例如英国国家医疗服务体系（NHS）。预计到2026年，英国市场规模将达到49.8亿美元，德国市场规模预计将达到75.1亿美元。

亚太地区

由于老龄人口不断增长以及医疗基础设施的不断完善，亚太地区预计将成为复合年增长率最高的地区。到2026年，日本市场预计将达到90.4亿美元，中国59.9亿美元，印度31.6亿美元。

拉丁美洲、中东和非洲

由于产品核准数量有限且市场渗透速度缓慢，预计这些地区的成长将较为温和。

主要企业

中枢神经系统（CNS）治疗市场的主要企业包括以下几家：

  • 百健
  • 辉瑞
  • F. Hoffmann-La Roche 有限公司
  • 诺华公司
  • 强生服务
  • 梯瓦製药工业公司
  • 赛诺菲
  • 大冢控股

这些公司正致力于扩大产品线、建立合作伙伴关係、核准监管机构批准以及扩大营运区域，以巩固其市场地位。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会

第四章：主要考虑因素

  • 产业重大发展动态－併购与合作
  • 新产品发布
  • 管道分析
  • 监理情势概述
  • 新冠疫情对市场的影响

第五章：全球中枢神经系统治疗市场分析、洞察与预测（2025-2034年）

  • 主要发现与总结
  • 市场分析、洞察与预测：按药物类别划分
    • 免疫调节药物
    • 干扰素
    • 脱羧酶抑制剂
    • 多巴胺促效剂
    • 抗忧郁症
    • 止痛药
    • 其他的
  • 市场分析、洞察与预测：按疾病类型划分
    • 神经血管疾病
      • 出血性中风
      • 缺血性中风
      • 其他的
    • 神经退化性疾病
      • 阿兹海默症
      • 帕金森氏症
      • 多发性硬化症
      • 其他的
    • 心理健康
      • 癫痫
      • 情绪障碍
      • 焦虑症
      • 其他的
      • 感染疾病
      • 脑膜炎
      • 脑炎
      • 其他的
    • 其他的
  • 市场分析、洞察与预测：按分销管道划分
    • 医院药房
    • 零售药房
    • 其他的
  • 市场分析、洞察与预测：按药物类型划分
    • 生物製药
    • 非生物製药
  • 市场分析、洞察与预测：按地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美中枢神经系统疗法市场分析、洞察与预测（2025-2034年）

  • 国家
    • 美国（依药物类型）
    • 加拿大（依药物类型）

第七章：欧洲中枢神经系统治疗市场分析、洞察与预测（2025-2034年）

  • 国家
    • 英国（依药物类型）
    • 德国（依药物类型）
    • 法国（依药物类型）
    • 西班牙（依毒品类型）
    • 义大利（依药物类型）
    • 斯堪地那维亚（按药物类型）
    • 其他欧洲国家（依药物类型）

第八章：亚太地区中枢神经系统治疗市场分析、洞察与预测（2025-2034年）

  • 国家
    • 日本（依药物类型）
    • 中国（依药品类型）
    • 印度（依药物类型）
    • 澳洲（依药物类型）
    • 东南亚（依药物类型）
    • 其他亚太地区（依药物类型）

第九章：拉丁美洲中枢神经系统治疗市场分析、洞察与预测（2025-2034年）

  • 国家
    • 巴西（按毒品类型）
    • 墨西哥（按毒品类型）
    • 其他拉丁美洲国家（依毒品类型）

第十章：中东和非洲中枢神经系统治疗市场分析、洞察与预测（2025-2034年）

  • 国家
    • 海湾合作委员会国家（按药物类型）
    • 南非（依药物类型）
    • 其他中东和非洲地区（按药物类型）

第十一章 竞争分析

  • 主要行业趋势
  • 全球市占率分析（2025 年）
  • 公司简介
    • Biogen
    • Pfizer, Inc.
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Johnson and Johnson Services Inc.
    • Teva Pharmaceutical Industries Lt
    • Sanofi
    • Otsuka Holdings
    • Other Prominent Players
Product Code: FBI103973

Growth Factors of central nervous system (CNS) treatment Market

The global central nervous system (CNS) treatment market was valued at USD 126.68 billion in 2025 and is projected to grow to USD 138.66 billion in 2026, reaching USD 236.94 billion by 2034, registering a CAGR of 6.93% during 2026-2034. North America dominated the market in 2025, accounting for 45.70% of the global share, supported by strong regulatory frameworks, high treatment accessibility, and the presence of leading pharmaceutical companies.

The CNS treatment market includes therapies for neurodegenerative diseases, neurovascular disorders, mental health conditions, infectious neurological diseases, and others. Rising prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis is significantly contributing to market expansion.

COVID-19 Impact

The COVID-19 pandemic had a negative impact on the CNS treatment market, resulting in a -4.2% decline in 2024. Pharmaceutical companies shifted their R&D focus toward COVID-19 vaccines and therapeutics, causing an estimated USD 115.84 billion sales drop in 2024. However, the market rebounded in 2025 as demand returned to pre-pandemic levels and drug development activities resumed.

Market Drivers

Growing Prevalence of Neurological Disorders

The increasing global burden of neurological diseases is a primary growth driver. In the U.S., around 6 million people live with Alzheimer's disease, and this number is projected to rise significantly in the coming decades. The annual treatment and care costs exceed USD 305 billion, creating strong demand for effective CNS therapeutics.

Additionally, rising cases of multiple sclerosis, Parkinson's disease, epilepsy, and mental health disorders are expanding the patient pool. Growing geriatric populations worldwide further accelerate demand for advanced treatment options.

Promising Pipeline Drugs

Several innovative molecules and biologics in late-stage clinical trials are expected to strengthen the market outlook. Strategic collaborations and licensing agreements between pharmaceutical companies are increasing drug development efficiency and global commercialization opportunities.

Market Restraints

Despite growth prospects, the CNS treatment market faces notable challenges:

  • Stringent regulatory approvals
  • High R&D costs
  • Long clinical development timelines
  • Difficulty in crossing the blood-brain barrier
  • Adverse drug reactions and safety warnings

For example, in 2025, the U.S. FDA issued safety warnings regarding certain multiple sclerosis drugs, highlighting potential treatment risks. These factors may limit market growth during the forecast period.

Market Segmentation Analysis

By Disease Type

  • Neurodegenerative diseases dominated the market with a 47.08% share in 2026, driven by high sales of multiple sclerosis and Alzheimer's drugs.
  • Mental health disorders are witnessing rising demand due to increased global awareness and post-pandemic psychological stress.
  • Neurovascular and infectious diseases also contribute to steady market growth.

By Drug Class

  • Immunomodulators led the market in 2026 with a 52.08% share, supported by innovation in multiple sclerosis therapies.
  • Interferons, antidepressants, dopamine agonists, analgesics, and other CNS drugs contribute significantly to overall revenue.

By Drug Type

  • Non-biologics dominated the market with a 69.05% share in 2026, owing to easier regulatory approvals and strong prescription rates.
  • Biologics are expected to grow steadily due to supportive government initiatives and expanding biologic pipelines.

By Distribution Channel

  • Hospital pharmacies held the largest share due to high prescription drug sales and preference for hospital-based treatments.
  • Retail pharmacies and online pharmacies are expanding, particularly in emerging markets.

Regional Insights

North America

North America generated USD 57.96 billion in 2025 and USD 63.13 billion in 2026. The U.S. market alone is projected to reach USD 58.25 billion in 2026. Growth is driven by strong R&D infrastructure, high disease prevalence, regulatory support from the FDA, and robust reimbursement systems.

Europe

Europe holds the second-largest market share, supported by favorable reimbursement policies and public healthcare systems such as the NHS. The UK market is projected to reach USD 4.98 billion in 2026, while Germany is projected at USD 7.51 billion in 2026.

Asia Pacific

Asia Pacific is expected to register the highest CAGR due to increasing geriatric populations and improving healthcare infrastructure. The Japan market is projected to reach USD 9.04 billion in 2026, China USD 5.99 billion, and India USD 3.16 billion.

Latin America & Middle East & Africa

These regions are expected to witness moderate growth due to limited product approvals and slower market penetration.

Key Industry Players

Major companies operating in the CNS treatment market include:

  • Biogen
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Otsuka Holdings

These companies focus on pipeline expansion, partnerships, regulatory approvals, and geographic expansion to strengthen their market positions.

Conclusion

The global CNS treatment market is poised for steady expansion from USD 126.68 billion in 2025 to USD 236.94 billion by 2034, driven by rising neurological disease prevalence, increasing geriatric population, strong R&D pipelines, and improved treatment accessibility. Although regulatory complexities and high development costs present challenges, continued innovation, strategic partnerships, and expanding healthcare infrastructure are expected to sustain long-term market growth across major regions.

Segmentation By Disease Type

  • Neurovascular Diseases
    • Hemorrhagic Stroke
    • Ischemic Stroke
    • Others
  • Neurodegenerative Diseases
    • Alzheimer's Disease
    • Parkinson's Disease
    • Multiple Sclerosis
    • Others
  • Mental Health
    • Epilepsy
    • Mood Disorders
    • Anxiety Disorders
    • Others
  • Infectious Diseases
    • Meningitis
    • Encephalitis
    • Others
  • Others

By Drug Class

  • Immunomodulatory Drugs
  • Interferons
  • Decarboxylase Inhibitors
  • Dopamine Agonists
  • Antidepressants
  • Analgesics
  • Others

By Drug Type

  • Biologics
  • Non-biologics

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Disease Type, By Drug Class, By Drug Type By Distribution Channel, and By Country)
    • U.S. (By Drug Type)
    • Canada (By Drug Type)
  • Europe (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and By Country)
    • U.K. (By Drug Type)
    • Germany (By Drug Type)
    • France (By Drug Type)
    • Italy (By Drug Type)
    • Spain (By Drug Type)
    • Rest of Europe (By Drug Type)
  • Asia Pacific (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and By Country)
    • China (By Drug Type)
    • Japan (By Drug Type)
    • India (By Drug Type)
    • Australia (By Drug Type)
    • Southeast Asia (By Drug Type)
    • Rest of Asia Pacific (By Drug Type)
  • Latin America (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and by Country)
    • Brazil (By Drug Type)
    • Mexico (By Drug Type)
    • Rest of Latin America (By Drug Type)
  • Middle East & Africa (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and by Country)
    • GCC (By Drug Type)
    • South Africa (By Drug Type)
    • Rest of Middle East & Africa (By Drug Type)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Key Industry Developments- Mergers, Acquisitions and Partnerships
  • 4.2. New Product Launches
  • 4.3. Pipeline Analysis
  • 4.4. Overview of Regulatory Scenario
  • 4.5. Impact of COVID-19 on the Market

5. Global Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Drug Class
    • 5.2.1. Immunomodulatory Drugs
    • 5.2.2. Interferons
    • 5.2.3. Decarboxylase Inhibitors
    • 5.2.4. Dopamine Agonists
    • 5.2.5. Antidepressants
    • 5.2.6. Analgesics
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By Disease Type
    • 5.3.1. Neurovascular Diseases
      • 5.3.1.1. Hemorrhagic Stroke
      • 5.3.1.2. Ischemic Stroke
      • 5.3.1.3. Others
    • 5.3.2. Neurodegenerative Diseases
      • 5.3.2.1. Alzheimer's Disease
      • 5.3.2.2. Parkinson's Disease
      • 5.3.2.3. Multiple Sclerosis
      • 5.3.2.4. Others
    • 5.3.3. Mental Health
      • 5.3.3.1. Epilepsy
      • 5.3.3.2. Mood Disorders
      • 5.3.3.3. Anxiety Disorders
      • 5.3.3.4. Others
      • 5.3.3.5. Infectious Diseases
      • 5.3.3.6. Meningitis
      • 5.3.3.7. Encephalitis
      • 5.3.3.8. Others
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacy
    • 5.4.2. Retail Pharmacy
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Drug Type
    • 5.5.1. Biologics
    • 5.5.2. Non-biologics
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis, Insights and Forecast - By Drug Class
    • 6.2.1. Immunomodulatory Drugs
    • 6.2.2. Interferons
    • 6.2.3. Decarboxylase Inhibitors
    • 6.2.4. Dopamine Agonists
    • 6.2.5. Antidepressants
    • 6.2.6. Analgesics
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By Disease Type
    • 6.3.1. Neurovascular Diseases
      • 6.3.1.1. Hemorrhagic Stroke
      • 6.3.1.2. Ischemic Stroke
      • 6.3.1.3. Others
    • 6.3.2. Neurodegenerative Diseases
      • 6.3.2.1. Alzheimer's Disease
      • 6.3.2.2. Parkinson's Disease
      • 6.3.2.3. Multiple Sclerosis
      • 6.3.2.4. Others
    • 6.3.3. Mental Health
      • 6.3.3.1. Epilepsy
      • 6.3.3.2. Mood Disorders
      • 6.3.3.3. Anxiety Disorders
      • 6.3.3.4. Others
      • 6.3.3.5. Infectious Diseases
      • 6.3.3.6. Meningitis
      • 6.3.3.7. Encephalitis
      • 6.3.3.8. Others
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacy
    • 6.4.2. Retail Pharmacy
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Drug Type
    • 6.5.1. Biologics
    • 6.5.2. Non-biologics
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S. (By Drug Type)
    • 6.6.2. Canada (By Drug Type)

7. Europe Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis, Insights and Forecast - By Drug Class
    • 7.2.1. Immunomodulatory Drugs
    • 7.2.2. Interferons
    • 7.2.3. Decarboxylase Inhibitors
    • 7.2.4. Dopamine Agonists
    • 7.2.5. Antidepressants
    • 7.2.6. Analgesics
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By Disease Type
    • 7.3.1. Neurovascular Diseases
      • 7.3.1.1. Hemorrhagic Stroke
      • 7.3.1.2. Ischemic Stroke
      • 7.3.1.3. Others
    • 7.3.2. Neurodegenerative Diseases
      • 7.3.2.1. Alzheimer's Disease
      • 7.3.2.2. Parkinson's Disease
      • 7.3.2.3. Multiple Sclerosis
      • 7.3.2.4. Others
    • 7.3.3. Mental Health
      • 7.3.3.1. Epilepsy
      • 7.3.3.2. Mood Disorders
      • 7.3.3.3. Anxiety Disorders
      • 7.3.3.4. Others
      • 7.3.3.5. Infectious Diseases
      • 7.3.3.6. Meningitis
      • 7.3.3.7. Encephalitis
      • 7.3.3.8. Others
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacy
    • 7.4.2. Retail Pharmacy
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Drug Type
    • 7.5.1. Biologics
    • 7.5.2. Non-biologics
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.6.1. U.K. (By Drug Type)
    • 7.6.2. Germany (By Drug Type)
    • 7.6.3. France (By Drug Type)
    • 7.6.4. Spain (By Drug Type)
    • 7.6.5. Italy (By Drug Type)
    • 7.6.6. Scandinavia (By Drug Type)
    • 7.6.7. Rest of Europe (By Drug Type)

8. Asia Pacific Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis, Insights and Forecast - By Drug Class
    • 8.2.1. Immunomodulatory Drugs
    • 8.2.2. Interferons
    • 8.2.3. Decarboxylase Inhibitors
    • 8.2.4. Dopamine Agonists
    • 8.2.5. Antidepressants
    • 8.2.6. Analgesics
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By Disease Type
    • 8.3.1. Neurovascular Diseases
      • 8.3.1.1. Hemorrhagic Stroke
      • 8.3.1.2. Ischemic Stroke
      • 8.3.1.3. Others
    • 8.3.2. Neurodegenerative Diseases
      • 8.3.2.1. Alzheimer's Disease
      • 8.3.2.2. Parkinson's Disease
      • 8.3.2.3. Multiple Sclerosis
      • 8.3.2.4. Others
    • 8.3.3. Mental Health
      • 8.3.3.1. Epilepsy
      • 8.3.3.2. Mood Disorders
      • 8.3.3.3. Anxiety Disorders
      • 8.3.3.4. Others
      • 8.3.3.5. Infectious Diseases
      • 8.3.3.6. Meningitis
      • 8.3.3.7. Encephalitis
      • 8.3.3.8. Others
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Drug Type
    • 8.5.1. Biologics
    • 8.5.2. Non-biologics
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.6.1. Japan (By Drug Type)
    • 8.6.2. China (By Drug Type)
    • 8.6.3. India (By Drug Type)
    • 8.6.4. Australia (By Drug Type)
    • 8.6.5. Southeast Asia (By Drug Type)
    • 8.6.6. Rest of Asia Pacific (By Drug Type)

9. Latin America Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis, Insights and Forecast - By Drug Class
    • 9.2.1. Immunomodulatory Drugs
    • 9.2.2. Interferons
    • 9.2.3. Decarboxylase Inhibitors
    • 9.2.4. Dopamine Agonists
    • 9.2.5. Antidepressants
    • 9.2.6. Analgesics
    • 9.2.7. Others
  • 9.3. Market Analysis, Insights and Forecast - By Disease Type
    • 9.3.1. Neurovascular Diseases
      • 9.3.1.1. Hemorrhagic Stroke
      • 9.3.1.2. Ischemic Stroke
      • 9.3.1.3. Others
    • 9.3.2. Neurodegenerative Diseases
      • 9.3.2.1. Alzheimer's Disease
      • 9.3.2.2. Parkinson's Disease
      • 9.3.2.3. Multiple Sclerosis
      • 9.3.2.4. Others
    • 9.3.3. Mental Health
      • 9.3.3.1. Epilepsy
      • 9.3.3.2. Mood Disorders
      • 9.3.3.3. Anxiety Disorders
      • 9.3.3.4. Others
      • 9.3.3.5. Infectious Diseases
      • 9.3.3.6. Meningitis
      • 9.3.3.7. Encephalitis
      • 9.3.3.8. Others
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacy
    • 9.4.2. Retail Pharmacy
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Drug Type
    • 9.5.1. Biologics
    • 9.5.2. Non-biologics
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.6.1. Brazil (By Drug Type)
    • 9.6.2. Mexico (By Drug Type)
    • 9.6.3. Rest of Latin America (By Drug Type)

10. Middle East & Africa Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis, Insights and Forecast - By Drug Class
    • 10.2.1. Immunomodulatory Drugs
    • 10.2.2. Interferons
    • 10.2.3. Decarboxylase Inhibitors
    • 10.2.4. Dopamine Agonists
    • 10.2.5. Antidepressants
    • 10.2.6. Analgesics
    • 10.2.7. Others
  • 10.3. Market Analysis, Insights and Forecast - By Disease Type
    • 10.3.1. Neurovascular Diseases
      • 10.3.1.1. Hemorrhagic Stroke
      • 10.3.1.2. Ischemic Stroke
      • 10.3.1.3. Others
    • 10.3.2. Neurodegenerative Diseases
      • 10.3.2.1. Alzheimer's Disease
      • 10.3.2.2. Parkinson's Disease
      • 10.3.2.3. Multiple Sclerosis
      • 10.3.2.4. Others
    • 10.3.3. Mental Health
      • 10.3.3.1. Epilepsy
      • 10.3.3.2. Mood Disorders
      • 10.3.3.3. Anxiety Disorders
      • 10.3.3.4. Others
      • 10.3.3.5. Infectious Diseases
      • 10.3.3.6. Meningitis
      • 10.3.3.7. Encephalitis
      • 10.3.3.8. Others
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Drug Type
    • 10.5.1. Biologics
    • 10.5.2. Non-biologics
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.6.1. GCC Countries (By Drug Type)
    • 10.6.2. South Africa (By Drug Type)
    • 10.6.3. Rest of Middle East & Africa (By Drug Type)

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.3.1. Biogen
      • 11.3.1.1. Overview,
      • 11.3.1.2. Products,
      • 11.3.1.3. SWOT analysis,
      • 11.3.1.4. Recent developments,
      • 11.3.1.5. strategies,
      • 11.3.1.6. financials (based on availability)
    • 11.3.2. Pfizer, Inc.
      • 11.3.2.1. Overview,
      • 11.3.2.2. Products,
      • 11.3.2.3. SWOT analysis,
      • 11.3.2.4. Recent developments,
      • 11.3.2.5. strategies,
      • 11.3.2.6. financials (based on availability)
    • 11.3.3. F. Hoffmann-La Roche Ltd
      • 11.3.3.1. Overview,
      • 11.3.3.2. Products,
      • 11.3.3.3. SWOT analysis,
      • 11.3.3.4. Recent developments,
      • 11.3.3.5. strategies,
      • 11.3.3.6. financials (based on availability)
    • 11.3.4. Novartis AG
      • 11.3.4.1. Overview,
      • 11.3.4.2. Products,
      • 11.3.4.3. SWOT analysis,
      • 11.3.4.4. Recent developments,
      • 11.3.4.5. strategies,
      • 11.3.4.6. financials (based on availability)
    • 11.3.5. Johnson and Johnson Services Inc.
      • 11.3.5.1. Overview,
      • 11.3.5.2. Products,
      • 11.3.5.3. SWOT analysis,
      • 11.3.5.4. Recent developments,
      • 11.3.5.5. strategies,
      • 11.3.5.6. financials (based on availability)
    • 11.3.6. Teva Pharmaceutical Industries Lt
      • 11.3.6.1. Overview,
      • 11.3.6.2. Products,
      • 11.3.6.3. SWOT analysis,
      • 11.3.6.4. Recent developments,
      • 11.3.6.5. strategies,
      • 11.3.6.6. financials (based on availability)
    • 11.3.7. Sanofi
      • 11.3.7.1. Overview,
      • 11.3.7.2. Products,
      • 11.3.7.3. SWOT analysis,
      • 11.3.7.4. Recent developments,
      • 11.3.7.5. strategies,
      • 11.3.7.6. financials (based on availability)
    • 11.3.8. Otsuka Holdings
      • 11.3.8.1. Overview,
      • 11.3.8.2. Products,
      • 11.3.8.3. SWOT analysis,
      • 11.3.8.4. Recent developments,
      • 11.3.8.5. strategies,
      • 11.3.8.6. financials (based on availability)
    • 11.3.9. Other Prominent Players
      • 11.3.9.1. Overview,
      • 11.3.9.2. Products,
      • 11.3.9.3. SWOT analysis,
      • 11.3.9.4. Recent developments,
      • 11.3.9.5. strategies,
      • 11.3.9.6. financials (based on availability)

List of Tables

  • Table 1: Global Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2025-2034
  • Table 2: Global Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2025-2034
  • Table 3: Global Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 4: Global Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Region, 2025-2034
  • Table 5: North America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2025-2034
  • Table 6: North America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2025-2034
  • Table 7: North America Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 8: North America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Country, 2025-2034
  • Table 9: Europe Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2025-2034
  • Table 10: Europe Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2025-2034
  • Table 11: Europe Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 12: Europe Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
  • Table 13: Asia Pacific Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2025-2034
  • Table 14: Asia Pacific Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2025-2034
  • Table 15: Asia Pacific Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 16: Asia Pacific Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
  • Table 17: Latin America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2025-2034
  • Table 18: Latin America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2025-2034
  • Table 19: Latin America Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 20: Latin America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
  • Table 21: Middle East & Africa Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2025-2034
  • Table 22: Middle East & Africa Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2025-2034
  • Table 23: Middle East & Africa Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 24: Middle East & Africa Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034

List of Figures

  • Figure 1: Global Central Nervous System Treatment Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Central Nervous System Treatment Market Value Share (%), By Drug Class, 2025 & 2034
  • Figure 3: Global Central Nervous System Treatment Market Forecast (USD billion), by Multiple Sclerosis Drugs, 2025-2034
  • Figure 4: Global Central Nervous System Treatment Market Forecast (USD billion), by Anti-psychotic, 2025-2034
  • Figure 5: Global Central Nervous System Treatment Market Forecast (USD billion), by Anti-epileptic, 2025-2034
  • Figure 6: Global Central Nervous System Treatment Market Forecast (USD billion), by Antidepressants, 2025-2034
  • Figure 7: Global Central Nervous System Treatment Market Forecast (USD billion), by Psychostimulants, 2025-2034
  • Figure 8: Global Central Nervous System Treatment Market Forecast (USD billion), by Narcotic Analgesics, 2025-2034
  • Figure 9: Global Central Nervous System Treatment Market Forecast (USD billion), by Non-Narcotic Analgesics, 2025-2034
  • Figure 10: Global Central Nervous System Treatment Market Forecast (USD billion), by Anaesthetics, 2025-2034
  • Figure 11: Global Central Nervous System Treatment Market Forecast (USD billion), by Antiparkinsons, 2025-2034
  • Figure 12: Global Central Nervous System Treatment Market Forecast (USD billion), by Sedatives, 2025-2034
  • Figure 13: Global Central Nervous System Treatment Market Forecast (USD billion), by General Anaesthesia, 2025-2034
  • Figure 14: Global Central Nervous System Treatment Market Forecast (USD billion), by Other CNS Products, 2025-2034
  • Figure 15: Global Central Nervous System Treatment Market Value Share (%), by Drug Type, 2025 & 2034
  • Figure 16: Global Central Nervous System Treatment Market Value Share (%), by Biologics, 2025 & 2034
  • Figure 17: Global Central Nervous System Treatment Market Value Share (%), by Non-biologics, 2025 & 2034
  • Figure 18: Global Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 19: Global Central Nervous System Treatment Market Forecast (USD billion), by Hospital Pharmacy, 2025-2034
  • Figure 20: Global Central Nervous System Treatment Market Forecast (USD billion), by Retail Pharmacy, 2025-2034
  • Figure 21: Global Central Nervous System Treatment Market Forecast (USD billion), by Others, 2025-2034
  • Figure 22: Global Central Nervous System Treatment Market Value (USD billion), by Region, 2025 & 2034
  • Figure 23: North America Central Nervous System Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 24: North America Central Nervous System Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 25: North America Central Nervous System Treatment Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 26: North America Central Nervous System Treatment Market Value Share (%), By Drug Type, 2025
  • Figure 27: North America Central Nervous System Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 28: North America Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 29: North America Central Nervous System Treatment Market Value (USD billion), By Country, 2025 & 2034
  • Figure 30: North America Central Nervous System Treatment Market Value Share (%), By Country, 2025
  • Figure 31: Europe Central Nervous System Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 32: Europe Central Nervous System Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 33: Europe Central Nervous System Treatment Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 34: Europe Central Nervous System Treatment Market Value Share (%), By Drug Type, 2025
  • Figure 35: Europe Central Nervous System Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 36: Europe Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 37: Europe Central Nervous System Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 38: Europe Central Nervous System Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 39: Asia Pacific Central Nervous System Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 40: Asia Pacific Central Nervous System Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 41: Asia Pacific Central Nervous System Treatment Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 42: Asia Pacific Central Nervous System Treatment Market Value Share (%), By Drug Type, 2025
  • Figure 43: Asia Pacific Central Nervous System Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Asia Pacific Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Asia Pacific Central Nervous System Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Asia Pacific Central Nervous System Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Latin America Central Nervous System Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 48: Latin America Central Nervous System Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 49: Latin America Central Nervous System Treatment Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 50: Latin America Central Nervous System Treatment Market Value Share (%), By Drug Type, 2025
  • Figure 51: Latin America Central Nervous System Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 52: Latin America Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 53: Latin America Central Nervous System Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 54: Latin America Central Nervous System Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 55: Middle East & Africa Central Nervous System Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 56: Middle East & Africa Central Nervous System Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 57: Middle East & Africa Central Nervous System Treatment Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 58: Middle East & Africa Central Nervous System Treatment Market Value Share (%), By Drug Type, 2025
  • Figure 59: Middle East & Africa Central Nervous System Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 60: Middle East & Africa Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 61: Middle East & Africa Central Nervous System Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 62: Middle East & Africa Central Nervous System Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 63: Global Central Nervous System Treatment Market Share (%), By Company, 2025